ApconiX Welcomes Dr Bjorn Dahl

ApconiX is delighted to welcome Dr Björn Dahl to the team, who joins our new Swedish office at AstraZeneca’s BioVentureHub in Mölndal, Gothenburg.

Björn is a highly respected and experienced toxicologist, having been the co-chair of the European Federation Pharmaceutical Industry Association (EFPIA) Preclinical Development Expert Working Group and served as the EFPIA topic lead in the International Conference on Harmonisation (ICH) Expert Working Group developing a new guideline on nonclinical safety testing in support of development of paediatric medicines. Björn is a European Registered Toxicologist (ERT), a member of the Swedish Society of Toxicology as well as the Swedish National Registration board for ERT.

Björn has a BSc in biology and chemistry and a Ph.D. in Environmental Toxicology from Gothenburg University. Björn worked at Astra AB and AstraZeneca R&D for over 20 years in nonclinical safety and has had different management as well as portfolio leadership roles. Björn was a Toxicology Project Leader, before becoming the Therapeutic Area/Lead Toxicologist for the Cardiovascular, Renal and Metabolism (CVRM) research division. In that role, he was a member of nonclinical safety as well as CVRM portfolio governance teams.

“I am looking forward to use the experience gained from 23 years of supporting projects in early and late stage development to help biotech and pharma companies bring effective, safe drugs to market quickly,” added Björn.

Dr Richard Knight, Director and Co-Founder of ApconiX, commented “We are very excited that Björn is joining ApconiX at our Gothenburg office. Having worked with him for many years, I know he’s is one of the most capable toxicologists around, and he brings a wealth of experience in early and late stage development. His knowledge, pragmatic approach and network will further enhance our ability to provide clients with the best advice for their projects.”

By |2019-02-07T16:37:46+00:00February 6th, 2019|Toxicology, Careers|Comments Off on ApconiX Welcomes Dr Bjorn Dahl

About the Author:

Dr Richard Knight PhD, ERT, is a Director and Co-founder of ApconiX, a preclinical toxicology and ion channel company that brings together a team of world-renowned nonclinical safety experts. Richard graduated from the University of Bradford in 1989 with a degree in Biomedical Sciences (Pharmacology) before gaining a PhD at the University of Leeds researching the role of adenosine receptors in renal function and toxicity. His research then included post-doctoral studies at University of California, Los Angeles (UCLA) into the effects of ischaemia/reperfusion injury on cardiac metabolism. Richard joined Zeneca Pharmaceuticals, Safety of Medicines Group in 1996 as a Study Director, and then Project Toxicologist across multiple therapy areas, from early discovery through to market. As Lead Toxicologist for Oncology, Richard was a member of both the Drug Safety and Metabolism, and Oncology Leadership teams with responsibility for safety across the AZ oncology portfolio. In this senior role he provided leadership and mentoring support to other project toxicologists. Richard has worked on many drug platforms over this time including small molecules, biologics, proteins and oligonucleotides and has been involved in bringing over 30 new candidate drugs into clinical trials and 5 to marketing approval.